Can Amgen beat down payer resistance to Repatha with its own cost analysis?
PCSK9 heart drugs have proven to be one of the biggest commercial disappointments in recent biopharma times. Held back by payers who don’t see the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
